-
公开(公告)号：KR100991755B1
公开(公告)日：2010-11-03
申请号：KR1020070083990
申请日：2007-08-21
Applicant: 한국과학기술연구원
IPC: C12Q1/68
Abstract: 본 발명은 폐독성 유발 약물 검색용 마커유전자 및 이를 이용한 검색 방법에 관한 것으로, 더욱 상세하게는 폐독성 유발 약물인 카르바마제핀(carbamazepine)에 의해 유전자 발현이 증가 또는 감소하는 마커유전자 및 이를 이용한 폐독성 유발 약물의 검색 방법에 관한 것이다. 본 발명의 마커유전자는 DNA 마이크로어레이 칩을 통하여 선별된 반응 유전자들을 마커유전자로 이용하여 폐독성의 위험성을 지닌 약물 또는 화학물질을 모니터링 및 판정하는데 유용하게 사용될 수 있으며, 카르바마제핀이 폐독성 및 부작용을 일으키는 작용 기작을 규명하는 도구로 이용될 수 있다.
카르바마제핀, 마커유전자, 마이크로어레이, 폐독성-
公开(公告)号：KR100962185B1
公开(公告)日：2010-06-10
申请号：KR1020070114256
申请日：2007-11-09
Applicant: 한국과학기술연구원
Abstract: 본 발명은 심혈관독성 유발 약물 검색용 마커유전자 및 이를 이용한 검색 방법에 관한 것으로, 더욱 상세하게는 심혈관독성 유발 약물인 다우노루비신(Daunorubicin)에 의해 유전자 발현이 증가 또는 감소하는 마커유전자 및 이를 이용한 심혈관독성 유발 약물의 검색 방법에 관한 것이다. 본 발명의 마커유전자는 DNA 마이크로어레이 칩을 통하여 선별된 반응 유전자들을 마커유전자로 이용하여 심혈관독성의 위험성을 지닌 약물 또는 화학물질을 모니터링 및 판정하는데 유용하게 사용될 수 있으며, 다우노루비신이 심혈관독성 및 부작용을 일으키는 작용 기작을 규명하는 도구로 이용될 수 있다.
다우노루비신, 마커유전자, 마이크로어레이, 심혈관독성-
公开(公告)号：KR1020100005366A
公开(公告)日：2010-01-15
申请号：KR1020080065367
申请日：2008-07-07
Applicant: 한국과학기술연구원
CPC classification number: C12Q1/6883 , C12Q2600/136 , C40B40/06
Abstract: PURPOSE: A biomarker for screening teratogenicity-inducing chemical is provided to increase or decrease gene expression by methotrexate treatment and monitor chemical. CONSTITUTION: A gene expression of biomarker for screening teratogenicity-inducing chemical is increased or decreased by treating with a drug. The drug is methotrexate. A DNA microarray chip for screening the chemical comprises oligonucleotide containing whole or partial biomarker gene or its complementary oligonucleotide. A method for screening the chemical comprises: a step of treating test compound to human placenta-derived cells; a step of isolating RNA from the compound-treated experimental group and control group; a step of synthesizing cDNA and labeling the experimental group and control group with different color fluorescence; a step of hybridizing cDNA with DNA microarray chip; a step of analyzing DNA microarray chip; and a step of comparing experimental group with the control group.
Abstract translation: 目的：提供用于筛选致畸性诱导化学物质的生物标志物，以通过甲氨蝶呤治疗和监测化学药物来增加或减少基因表达。 构成：通过用药物治疗来增加或减少用于筛选致畸性诱导化学物质的生物标志物的基因表达。 药物是甲氨蝶呤。 用于筛选化学品的DNA微阵列芯片包含含有全部或部分生物标记基因或其互补寡核苷酸的寡核苷酸。 用于筛选化学品的方法包括：将测试化合物处理到人胎盘来源的细胞的步骤; 从化合物处理的实验组和对照组中分离RNA的步骤; 合成cDNA并用不同颜色荧光标记实验组和对照组的步骤; 将cDNA与DNA微阵列芯片杂交的步骤; 分析DNA微阵列芯片的步骤; 并将实验组与对照组进行比较。
-
公开(公告)号：KR1020090097364A
公开(公告)日：2009-09-16
申请号：KR1020080022450
申请日：2008-03-11
Applicant: 한국과학기술연구원
CPC classification number: C40B40/06 , C12Q1/6837 , C12Q2561/113 , G01N33/5067 , G01N2800/085
Abstract: A biomarker for identifying the exposure to malachite green is provided to specifically increase or decrease the expression by the malachite green and monitor the pollution by the malachite green. A biomarker for identifying the exposure to a malachite green comprises: a gene registration number (GeneBank) AB000584(Growth differentiation factor 15); a gene registration number NM_030581(Homo sapiens WD repeat domain 59)(WDR59); a gene registration number AK026623(Homo sapiens nuclear-encoded mitochondrial cytochrome C oxidase Va subunit); and a gene registration number DQ282439(Homo sapiens isolate B2-1-06 mitochondrion(cytochrome C oxidase subunit1). A method for identifying the exposure to the malachite green comprises: a step of isolating RNA from a human somatic cells and control somatic cells; a step of synthesizing RNA to cDNA (complementary DNA); a step of hybridizing the cDNA with DNA microarray chip; a step of analyzing DNA microarray chip; and comparing the expression level between control group and sample group.
Abstract translation: 提供用于鉴定孔雀石绿暴露的生物标志物，以特异性地增加或减少孔雀石绿的表达，并监测孔雀石绿的污染。 用于鉴定孔雀石绿的暴露的生物标志物包括：基因登记号（GeneBank）AB000584（生长分化因子15）; 基因登记号NM_030581（智人WD重复域59）（WDR59）; 基因注册号AK026623（人类核编码线粒体细胞色素C氧化酶Va亚基）; 和基因登记号DQ282439（智人分离株B2-1-06线粒体（细胞色素C氧化酶亚单位1）），鉴定孔雀绿暴露的方法包括：从人体细胞分离RNA并控制体细胞的步骤; 将cDNA合成到cDNA（互补DNA）的步骤;将cDNA与DNA微阵列芯片杂交的步骤;分析DNA微阵列芯片的步骤;比较对照组和样品组之间的表达水平。
-
公开(公告)号：KR100901128B1
公开(公告)日：2009-06-04
申请号：KR1020070069274
申请日：2007-07-10
Applicant: 한국과학기술연구원
IPC: C12Q1/68
Abstract: 본 발명은 최기형성 유발 약물 검색용 마커유전자 및 이를 이용한 검색 방법에 관한 것으로, 구체적으로 최기형성 유발 약물인 탈리도마이드 (Thalidomide)에 의해 유전자 발현이 증가 또는 감소하는 마커유전자 및 이를 이용한 탈리도마이드의 검색 방법에 관한 것이다. 본 발명의 마커유전자는 DNA 마이크로어레이 칩을 통하여 선별된 반응 유전자들을 마커유전자로 이용하여 새로운 최기형성 위험성을 지닌 약물 또는 화학물질 모니터링 및 위해성을 판정하는데 유용하며, 최기형성을 일으키는 작용 기작을 규명하는 도구로 이용될 수 있다.
탈리도마이드, 마커유전자, 마이크로어레이, 최기형성-
Patent Agency Ranking
公开(公告)号：KR1020090005880A
公开(公告)日：2009-01-14
申请号：KR1020070069274
申请日：2007-07-10
Applicant: 한국과학기술연구원
IPC: C12Q1/68
CPC classification number: C12Q1/6837 , C12Q1/6883 , C12Q2600/136 , C12Q2600/158
Abstract: A marker gene, a DNA microarray chip for screening the teratogenecity inducing drugs, and a method for screening the teratogenecity inducing drugs by using the chip are provided to the drugs inducing teratogenecity to be screened effectively. A marker gene is used to screen the teratogenecity inducing drugs and comprises the gene selected from Genebank NM_032199 [AT rich interactive domain 5B (MRF1-like)], Genebank BX647857 [Ankyrin repeat and SOCS box-containing 5], Genebank NM_013314 [B-cell linker], Genebank AB018258 [ATPase, Class V, type 10B], Genebank BX111592 [Transcribed locus], etc.
Abstract translation: 提供了用于筛选致畸性诱导药物的标记基因，用于筛选致畸性诱导药物的DNA微阵列芯片，以及通过使用芯片筛选致畸性诱导药物的方法，用于诱导致畸性的药物被有效筛选。 使用标记基因筛选致畸性诱导药物，并且包含选自Genebank NM_032199 [AT丰富的交互结构域5B（MRF1样）]，Genebank BX647857 [Ankyrin repeat and SOCS box-containing 5]，Genebank NM_013314 [B- 细胞接头]，Genebank AB018258 [ATPase，V类，10B型]，Genebank BX111592 [Transcribed轨迹]等
-
公开(公告)号：KR1020080038583A
公开(公告)日：2008-05-07
申请号：KR1020060105644
申请日：2006-10-30
Applicant: 한국과학기술연구원
CPC classification number: C12Q1/6837 , C12Q2563/107 , G01N33/5014 , G01N33/5302 , G01N33/5308
Abstract: A biomarker is provided to be usefully used in order to monitor and determine a volatile organic compound which is harmful to environment or real life using reaction genes selected through a DNA microarray chip and be used as a tool for investigating mechanism how the volatile organic compound causes toxicity. A biomarker for screening a volatile organic compound includes a gene selected from the group consisting of Genebank BC071718[Chemokine(C-C motif) ligand 4-like 1], Genebank NM_022168(Interferon induced with helicase C domain 1), Genebank AK095515(Interferon-induced protein with tetratricopeptide repeats 1), Genebank CD521853[Chemokine(C-C motif) ligand 4], Genebank AK023956(2'-5'-oligoadenylate synthetase-like), Genebank BC032839(Interferon-induced protein with tetratricopeptide repeats 2), Genebank AF026939(Interferon-induced protein with tetratricopeptide repeats 3), Genebank BX649185[B-cell CLL/lymphoma 6(zinc finger protein 51)], Genebank AI742278(Interleukin 8), Genebank X74328[Cannabinoid receptor 2(macrophage)], Genebank BF690887(BCL2-related protein A1), Genebank NM_001165(Baculoviral IAP repeat-containing 3), Genebank D90070(Phorbol-12-myristate-13-acetate-induced protein 1), Genebank M83221(V-rel reticuloendotheliosis viral oncogene homolog B), Genebank NM_004430(Early growth response 3), Genebank AK123009(Growth factor independent 1), Genebank NM_003764(Syntaxin 11), Genebank NM_014331(Solute carrier family 7, member 11), Genebank NM_000104(Cytochrome P450, family 1, subfamily B, polypeptide 1), Genebank AY123223(Sestrin 2), Genebank NM_002395[Malic enzyme 1, NADP(+)-dependent, cytosolic], Genebank NM_024625(Zinc finger CCCH-type, antiviral 1), Genebank AF302505[Pellino homolog 1(Drosophila)], Genebank AL834442(Nuclear receptor coactivator 7), Genebank NM_017414(Ubiquitin specific peptidase 18), Genebank NM_002133[Heme oxygenase (decycling) 1], Genebank AY337518(Hect domain and RLD 5), Genebank D80008(DNA replication complex GINS protein PSF1). A DNA microarray chip for searching the volatile organic compound is characterized in that an oligonucleotide or a complementary strand molecule including a total or a portion of the biomarker gene sequence is integrated. A method for screening the volatile organic compound comprises the steps of: (a) treating a human myelogenous leukemia cell with a compound to be tested; (b) isolating RNA respectively from the test group treated with the compound to be tested and a control group not treated with the compound to be tested; (c) labelling the test group and the control group respectively with a fluorescent material different from each other with synthesizing the RNA into cDNA; (d) hybridizing the cDNA labelled with the fluorescent material into the DNA microarray chip; (e) analyzing the reacted DNA microarray chip; and (f) comparing the expression degree of the biomarker with the data analyzed from the step(e). A kit for screening the volatile organic compound includes the DNA microarray chip.
Abstract translation: 提供生物标志物以有效地用于监测和确定使用通过DNA微阵列芯片选择的反应基因对环境或现实生活有害的挥发性有机化合物，并且用作调查机理如何使挥发性有机化合物引起的工具 毒性。 用于筛选挥发性有机化合物的生物标志物包括选自Genebank BC071718 [趋化因子（CC基序）配体4-样1]，Genebank NM_022168（用解旋酶C结构域1诱导的干扰素），Genebank AK095515（干扰素诱导的 具有四肽重复序列的蛋白质1），Genebank CD521853 [趋化因子（CC基序）配体4]，Genebank AK023956（2'-5'-oligoadenylate synthetase-like），Genebank BC032839（干扰素诱导的具有四肽重复序列的蛋白质2），Genebank AF026939 干扰素诱导的蛋白与四肽重复序列3），Genebank BX649185 [B细胞CLL /淋巴瘤6（锌指蛋白51）]，Genebank AI742278（白细胞介素8），Genebank X74328 [大麻素受体2（巨噬细胞）]，Genebank BF690887（BCL2 相关蛋白A1），Genebank NM_001165（含有杆状病毒IAP重复的3个），Genebank D90070（Phorbol-12-肉豆蔻酸-13-乙酸酯诱导的蛋白质1），Genebank M83221（V-rel网状内皮组织增生病毒癌基因同系物B），Genebank NM_004430 （早grow 基因库AK123009（生长因子独立1），Genebank NM_003764（Syntaxin 11），Genebank NM_014331（Solute carrier family 7，member 11），Genebank NM_000104（Cytochrome P450，family 1，subfamily B，polypeptide 1），Genebank AY123223（Sestrin 2），Genebank NM_002395 [Malic enzyme 1，NADP（+）-dependent，cytosolic]，Genebank NM_024625（Zinc finger CCCH-type，antiviral 1），Genebank AF302505 [Pellino homolog 1（Drosophila）]，Genebank AL834442 核受体共激活因子7），Genebank NM_017414（泛素特异性肽酶18），Genebank NM_002133 [血红素加氧酶（decycling）1]，Genebank AY337518（Hect结构域和RLD 5），Genebank D80008（DNA复制复合物GINS蛋白PSF1）。 用于搜索挥发性有机化合物的DNA微阵列芯片的特征在于整合了包含全部或部分生物标记基因序列的寡核苷酸或互补链分子。 用于筛选挥发性有机化合物的方法包括以下步骤：（a）用待测化合物处理人骨髓性白血病细胞; （b）分别从用待测化合物处理的试验组和未用待测化合物处理的对照组分离RNA; （c）分别用不同的荧光材料标记试验组和对照组，将RNA合成cDNA; （d）将用荧光材料标记的cDNA杂交到DNA微阵列芯片中; （e）分析反应的DNA微阵列芯片; 和（f）将生物标志物的表达程度与从步骤（e）分析的数据进行比较。 用于筛选挥发性有机化合物的试剂盒包括DNA微阵列芯片。
-
公开(公告)号：KR1020070120713A
公开(公告)日：2007-12-26
申请号：KR1020060055313
申请日：2006-06-20
Applicant: 한국과학기술연구원
CPC classification number: C12Q1/6827 , C12Q1/6837 , C12Q1/6844 , C12Q2563/107
Abstract: A marker gene is provided to determine candidate materials of mutagens having new carcinogenic possibility and be used for a kit of screening carcinogenic mutagens. A marker gene for screening carcinogenic mutagens is selected from the group consisting of: Genebank NM_003722, NM_001951, NM_006940, NM_005461, AF211977, NM_001337, NM_001643, NM_002309, AJ001348, NM_004310, AK027024, M26147, AF205437, NM_017753, NM_001974, NM_018659, NM_004519, NM_001171, NM_000339, L32786, NM_001647, AF134401, NM_007267, NM_001936, NM_012190, AK024433, NM_018199, NM_005510, AF110322, NM_006495, Y11162, NM_001711, AK024448, AB020695, AK024464, BE887356, AK022120, AL049434, AL389981, AK025673, AK024522, AF086548, AK000881, AK024365, AK023312, AK021573, AF007132, AK024759, AK021863, AF085917, S50185, NM_001141, S72620, NM_006399, NM_001244, AF118072, NM_003641, M26747, X99631, X52339, NM_000356, J03048, M81768, NM_001683, NM_016356, NM_003371, NM_001783, NM_003394, AF000562, Z36807, NM_015950, NM_015900, AB014541, AJ008151, NM_000715, NM_014509, S49432, AF210651, AF251187, U28131, NM_016301, NM_014081, NM_014151, L10374, AK026099, AL353948, AF088021, AK000107, AL359568, AF086183, AK023571, AF070586, AK024528, AK023515, AF090098 and NM_019060. The carcinogenic mutagens are selected from group consisting of 4-nitroquinoline-N-oxide, furylfuramide, methyl methanesulfonate, N-nitroso-N-methylurea, and 2-nitrofluorene.
Abstract translation: 提供标记基因以确定具有新的致癌可能性的诱变剂的候选物质，并用于筛选致癌致突变物的试剂盒。 用于筛选致癌性诱变剂的标记基因选自：Genebank NM_003722，NM_001951，NM_006940，NM_005461，AF211977，NM_001337，NM_001643，NM_002309，AJ001348，NM_004310，AK027024，M26147，AF205437，NM_017753，NM_001974，NM_018659，NM_004519， NM_001171，NM_001171，NM_001671，NM_001171，NM_000339，NM_001171，NM_001647，AF134401，NM_007267，NM_001936，NM_012190，AK024433，NM_018199，NM_005510，AF110322，NM_006495，Y11162，NM_001711，AK024448，AB020695，AK024464，BE887356，AK022120，AL049434，AL389981，AK025673，AK024522，AF086548， AK00881，AK000881，AK024365，AK023312，AK021573，AF007132，AK024759，AK021863，AF085917，S50185，NM_001141，S72620，NM_006399，NM_001244，AF118072，NM_003641，M26747，X99631，X52339，NM_000356，J03048，M81768，NM_001683，NM_016356，NM_003371，NM_001783， NM_003394，AF000562，Z36807，NM_015950，NM_015900，AB014541，AJ008151，NM_000715，NM_014509，S49432，AF210651，AF251187，U28131，NM_016301，NM_014081，NM_014151，L10374，AK026099，AL353948，AF088021，AK000107，AL359568 ，AF086183，AK023571，AF070586，AK024528，AK023515，AF090098和NM_019060。 致癌致突变体选自4-硝基喹啉-N-氧化物，呋喃基呋喃酰胺，甲磺酸甲酯，N-亚硝基-N-甲基脲和2-硝基芴。
-
19.发明授权
公开(公告)号：KR100713713B1
公开(公告)日：2007-05-07
申请号：KR1020050088257
申请日：2005-09-22
Applicant: 한국과학기술연구원
IPC: C12Q1/00
Abstract: 본 발명은 메틸수은(Methyl mercury) 노출 여부 진단용 바이오마커, 이를 이용하여 MeHg 노출을 진단하는 방법 및 MeHg에 대한 신경세포 보호제에 관한 것으로서, MeHg 노출시 발현 변화를 나타내는 SeW(selenoprotein W) 유전자 또는 단백질을 이용하면 MeHg의 노출 여부 진단에 유용하게 사용될 수 있으며, 글루타치온(GSH)은 MeHg의 독성으로부터 신경세포를 보호하는 신경세포 보호제로 이용될 수 있다.
Methyl mercury, neurotoxicity, Selenoprotein W-
公开(公告)号：KR1020000028711A
公开(公告)日：2000-05-25
申请号：KR1019990041208
申请日：1999-09-22
IPC: A61K31/47
CPC classification number: A61K31/472
Abstract: PURPOSE: Provided is a novel application of tetrahydroisoquinoline compound for a pharmaceutical composition, which could be used as a treatment for cardiac insufficiency, thrombosis, sepsis and/or disseminated intravascular coagulation(DIC). CONSTITUTION: Provided is a novel use of tetrahydroisoquinoline compounds which showcardiotonic and hypotensor effects, and suppression effects of platelet aggregation and iNOS(inducible NO syntheas) simultaneously in particular, a pharmaceutical composition comprising one or more of 1-alpha-naphthylmethy-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, and 1-beta-naphthylmethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoloine described in formula 1 and formula 2 respectively as available components is provided. The pharmaceutical compositions used as treatments for cardiac insufficiency such as infarction, chromic inflammation, hypertension, arteriosclerosis or congestive heart failure, thrombosis, sepsis and/or disseminated intravascular coagulation(DIC).
Abstract translation: 目的：提供四氢异喹啉化合物用于药物组合物的新型应用，可用于治疗心功能不全，血栓形成，败血症和/或弥散性血管内凝血（DIC）。 构成：提供了显示心力衰竭和低血压作用的四氢异喹啉化合物的新用途，特别是同时具有抑制血小板聚集和iNOS（诱导型NO合成）的作用的药物组合物，其包含1-α-萘基甲基-6,7 - 二羟基-1,2,3,4-四氢异喹啉和1-β-萘基甲基-6,7-二羟基-1,2,3,4-四氢异喹啉分别作为可得到的成分。 用作心脏功能不全的治疗药物组合物，如梗塞，铬炎症，高血压，动脉硬化或充血性心力衰竭，血栓形成，败血症和/或弥散性血管内凝血（DIC）。
-
-
-
-
-
-
-
-
-
Search Results
166
records
(took 0.046 seconds)
